Protara Therapeutics
TARA
48 hedge funds and large institutions have $157M invested in Protara Therapeutics in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 1 closing their positions.
1,500% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 1
45% more funds holding
Funds holding: 33 → 48 (+15)
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
33% more capital invested
Capital invested by funds: $118M → $157M (+$39.3M)
21.26% more ownership
Funds ownership: 67.81% → 89.06% (+21%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$14.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$14.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$10.4M |
| 4 |
O
OrbiMed
New York
|
+$10.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$765K |
| 2 |
EP
Eversept Partners
New York
|
-$232K |
| 3 |
HF
HRT Financial
New York
|
-$215K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$40.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.3K |
TARA Hedge Fund Activity: Q3 2020 in Review
48 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2020, worth a combined $157M — up 33% from $118M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TARA positions and 1 closed out — a net gain of 15 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Rock Springs Capital Management, opening a new position worth an estimated $14.9M. The largest seller was Abingworth, cutting an estimated $765K.
- 48 institutional investors held Protara Therapeutics (TARA) as of Q3 2020, up from 33 in Q2 2020.
- Funds reported $157M of Protara Therapeutics stock for Q3 2020, up 33% quarter-over-quarter.
- 16 funds opened new Protara Therapeutics positions in Q3 2020 and 1 closed out, a net change of +15 holders.
- The largest Protara Therapeutics buyer in Q3 2020 was Rock Springs Capital Management, an estimated $14.9M added.
- The largest Protara Therapeutics seller in Q3 2020 was Abingworth, an estimated $765K sold.
Based on aggregated 13F filings for Q3 2020.